Recent advances in the treatment of acromegaly

被引:3
作者
Aghi, Manish [1 ]
Blevins, Lewis S., Jr. [1 ]
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, Calif Ctr Pituitary Disorders, San Francisco, CA 94143 USA
关键词
acromegaly; growth hormone receptor antagonist; lanreotide; octreotide; pegvisomant; radiosurgery; somatostatin receptor analogs; transphenoidal surgery; FOLLOW-UP; RADIOSURGERY; PEGVISOMANT;
D O I
10.1097/MED.0b013e32832d88e4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Description of recent outcomes and approaches to the treatment of patients with de-novo and recurrent acromegaly. Recent findings Radiosurgery for acromegaly results in a higher likelihood of remission and an earlier time to remission than does conventional radiotherapy. Somatostatin analogs results in control of acromegaly and one half of patients. Combining treatment with pegvisomant and somatostatin analogs results in overall improved quality of life. Summary Existing treatments offer patients and their treating physicians opportunities to restore life expectancy to normal and reverse many of the symptoms and signs of acromegaly.
引用
收藏
页码:304 / 307
页数:4
相关论文
共 50 条
  • [31] Medical therapy of acromegaly in Turkey
    O. Celik
    P. Kadioglu
    Journal of Endocrinological Investigation, 2010, 33 : 592 - 598
  • [32] Approach of Acromegaly during Pregnancy
    Popescu, Alexandru Dan
    Carsote, Mara
    Valea, Ana
    Nicola, Andreea Gabriela
    Dascalu, Ionela Teodora
    Tirca, Tiberiu
    Abdul-Razzak, Jaqueline
    Tuculina, Mihaela Jana
    DIAGNOSTICS, 2022, 12 (11)
  • [33] Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly
    Nicholas A. Tritos
    Beverly M. K. Biller
    Pituitary, 2017, 20 : 129 - 135
  • [34] Efficacy of long-term lanreotide treatment in patients with acromegaly
    Toledano, Yoel
    Rot, Liat
    Greenman, Yona
    Orlovsky, Sophia
    Pauker, Yulia
    Olchovsky, David
    Eliash, Achia
    Bardicef, Orit
    Makhoul, Ofa
    Tsvetov, Gloria
    Gershinsky, Michal
    Cohen-Ouaqnine, Odile
    Ness-Abramof, Rosane
    Adnan, Zaina
    Ilany, Jacob
    Guttmann, Hadassah
    Sapir, Mazal
    Benbassat, Carlos
    Shimon, Ilan
    PITUITARY, 2009, 12 (04) : 285 - 293
  • [35] MEDICAL TREATMENT LANDSCAPE FOR ACTIVE ACROMEGALY IN A PITUITARY CENTER IN ISRAEL
    Masri-Iraqi, Hiba
    Akirov, Amit
    Shimon, Ilan
    ENDOCRINE PRACTICE, 2020, 26 (11) : 1298 - 1303
  • [36] Diagnostics and treatment of acromegaly - updated recommendations of the Polish Society of Endocrinology
    Bolanowski, Marek
    Ruchala, Marek
    Zgliczynski, Wojciech
    Kos-Kudla, Beata
    Hubalewska-Dydejczyk, Alicja
    Lewinski, Andrzej
    ENDOKRYNOLOGIA POLSKA, 2019, 70 (01) : 2 - 18
  • [37] Investigational drugs for the treatment of acromegaly: new agents to transform therapy
    Pirchio, Rosa
    Auriemma, Renata S.
    Vergura, Alice
    Pivonello, Rosario
    Colao, Annamaria
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (05) : 509 - 522
  • [38] Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly
    Tritos, Nicholas A.
    Biller, Beverly M. K.
    PITUITARY, 2017, 20 (01) : 129 - 135
  • [39] Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases
    Tanya Burton
    Elisabeth Le Nestour
    Tim Bancroft
    Maureen Neary
    Pituitary, 2013, 16 : 354 - 362
  • [40] Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases
    Burton, Tanya
    Le Nestour, Elisabeth
    Bancroft, Tim
    Neary, Maureen
    PITUITARY, 2013, 16 (03) : 354 - 362